Gemtuzumab Ozogamicin Drugs - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509240957

Publication Date:

September 24, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Gemtuzumab ozogamicin听is a drug-linked听monoclonal antibody听(an听antibody-drug conjugate) that was used to treat听acute myeloid leukemia听from 2000 to 2010.
The global market for Gemtuzumab Ozogamicin Drugs was estimated to be worth US$ 214.3 million in 2023 and is forecast to a readjusted size of US$ 179.5 million by 2030 with a CAGR of -2.5% during the forecast period 2024-2030
Gemtuzumab Ozogamicin is an antibody-drug conjugate used to treat certain types of acute myeloid leukemia (AML). Its efficacy in targeting CD33-expressing AML cells and inducing remission has driven market growth. The limited treatment options for CD33-positive AML contribute to its niche status. However, challenges include potential side effects and the need for careful patient selection. The market competition is relatively small, as Gemtuzumab Ozogamicin remains a targeted therapy for a specific AML subgroup. Despite challenges, the Gemtuzumab Ozogamicin market offers potential for growth as healthcare providers seek effective treatments for patients with CD33-positive AML. Continued research and clinical advancements can further drive market expansion.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gemtuzumab Ozogamicin Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Gemtuzumab Ozogamicin Drugs by region & country, by Type, and by Application.
The Gemtuzumab Ozogamicin Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gemtuzumab Ozogamicin Drugs.
麻豆原创 Segmentation
By Company
Pfizer
Segment by Type:
5mg/Vial
4.5mg/Vial
Segment by Application
Hospital
Pharmacy
By Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gemtuzumab Ozogamicin Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Gemtuzumab Ozogamicin Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Gemtuzumab Ozogamicin Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Gemtuzumab Ozogamicin Drugs Product Introduction
1.2 Global Gemtuzumab Ozogamicin Drugs 麻豆原创 Size Forecast
1.2.1 Global Gemtuzumab Ozogamicin Drugs Sales Value (2019-2030)
1.2.2 Global Gemtuzumab Ozogamicin Drugs Sales Volume (2019-2030)
1.2.3 Global Gemtuzumab Ozogamicin Drugs Sales Price (2019-2030)
1.3 Gemtuzumab Ozogamicin Drugs 麻豆原创 Trends & Drivers
1.3.1 Gemtuzumab Ozogamicin Drugs Industry Trends
1.3.2 Gemtuzumab Ozogamicin Drugs 麻豆原创 Drivers & Opportunity
1.3.3 Gemtuzumab Ozogamicin Drugs 麻豆原创 Challenges
1.3.4 Gemtuzumab Ozogamicin Drugs 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gemtuzumab Ozogamicin Drugs Players Revenue Ranking (2023)
2.2 Global Gemtuzumab Ozogamicin Drugs Revenue by Company (2019-2024)
2.3 Global Gemtuzumab Ozogamicin Drugs Players Sales Volume Ranking (2023)
2.4 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Gemtuzumab Ozogamicin Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Gemtuzumab Ozogamicin Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Gemtuzumab Ozogamicin Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Gemtuzumab Ozogamicin Drugs
2.9 Gemtuzumab Ozogamicin Drugs 麻豆原创 Competitive Analysis
2.9.1 Gemtuzumab Ozogamicin Drugs 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Gemtuzumab Ozogamicin Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gemtuzumab Ozogamicin Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 5mg/Vial
3.1.2 4.5mg/Vial
3.2 Global Gemtuzumab Ozogamicin Drugs Sales Value by Type
3.2.1 Global Gemtuzumab Ozogamicin Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Gemtuzumab Ozogamicin Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Gemtuzumab Ozogamicin Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Type
3.3.1 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Gemtuzumab Ozogamicin Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Gemtuzumab Ozogamicin Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Gemtuzumab Ozogamicin Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.2 Global Gemtuzumab Ozogamicin Drugs Sales Value by Application
4.2.1 Global Gemtuzumab Ozogamicin Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Gemtuzumab Ozogamicin Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Gemtuzumab Ozogamicin Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Application
4.3.1 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Gemtuzumab Ozogamicin Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Gemtuzumab Ozogamicin Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Gemtuzumab Ozogamicin Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Gemtuzumab Ozogamicin Drugs Sales Value by Region
5.1.1 Global Gemtuzumab Ozogamicin Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Gemtuzumab Ozogamicin Drugs Sales Value by Region (2019-2024)
5.1.3 Global Gemtuzumab Ozogamicin Drugs Sales Value by Region (2025-2030)
5.1.4 Global Gemtuzumab Ozogamicin Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Region
5.2.1 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Gemtuzumab Ozogamicin Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Gemtuzumab Ozogamicin Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
5.4.2 North America Gemtuzumab Ozogamicin Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
5.5.2 Europe Gemtuzumab Ozogamicin Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Gemtuzumab Ozogamicin Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
5.7.2 South America Gemtuzumab Ozogamicin Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Gemtuzumab Ozogamicin Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gemtuzumab Ozogamicin Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Gemtuzumab Ozogamicin Drugs Sales Value
6.2.1 Key Countries/Regions Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Gemtuzumab Ozogamicin Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.3.2 United States Gemtuzumab Ozogamicin Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Gemtuzumab Ozogamicin Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.4.2 Europe Gemtuzumab Ozogamicin Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Gemtuzumab Ozogamicin Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.5.2 China Gemtuzumab Ozogamicin Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Gemtuzumab Ozogamicin Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.6.2 Japan Gemtuzumab Ozogamicin Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Gemtuzumab Ozogamicin Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.7.2 South Korea Gemtuzumab Ozogamicin Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Gemtuzumab Ozogamicin Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Gemtuzumab Ozogamicin Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Gemtuzumab Ozogamicin Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Gemtuzumab Ozogamicin Drugs Sales Value, 2019-2030
6.9.2 India Gemtuzumab Ozogamicin Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Gemtuzumab Ozogamicin Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Gemtuzumab Ozogamicin Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Gemtuzumab Ozogamicin Drugs Product Offerings
7.1.5 Pfizer Recent Development
8 Industry Chain Analysis
8.1 Gemtuzumab Ozogamicin Drugs Industrial Chain
8.2 Gemtuzumab Ozogamicin Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gemtuzumab Ozogamicin Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Gemtuzumab Ozogamicin Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Pfizer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.